| Identification | Back Directory | [Name]
AZITHROMYCIN-D3 | [CAS]
163921-65-1 | [Synonyms]
XZ-450-d3
Sumamed-d3
CP-62993-d3
Ribotrex-d3
Zitromax-d3
Azitrocin-d3
Trozocina-d3
Zithromaz-d3
AZITHROMYCIN-D3 | [Molecular Formula]
C38H72N2O12 | [MDL Number]
MFCD09839972 | [MOL File]
163921-65-1.mol | [Molecular Weight]
748.984 |
| Chemical Properties | Back Directory | [Appearance]
White Solid | [Melting point ]
125-1290C | [storage temp. ]
-20°C Freezer, Under Inert Atmosphere | [solubility ]
Chloroform (Slightly, Sonicated), Methanol (Slightly) | [form ]
Solid | [color ]
White to Off-White | [EPA Substance Registry System]
1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-?-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,8,10,12,14-hexamethyl-6-(methyl-d3)-11-[[3,4,6-trideoxy-3-(dimethylamino)-?-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (163921-65-1) |
| Hazard Information | Back Directory | [Chemical Properties]
White Solid | [Uses]
Semi-synthetic macrolide antibiotic; related to Erythromycin A. Antibacterial.;Labeled Azithromycin, intended for use as an internal standard for the quantification of Azithromycin by GC- or LC-mass spectrometry. | [Description]
Azithromycin-d3 is intended for use as an internal standard for the quantification of azithromycin (Item No. 15004) by GC- or LC-MS. Azithromycin is a macrolide antibiotic. It is active against S. pneumoniae, S. aureus, N. gonorrhoeae, M. pneumoniae, H. pylori, C. trachomatis, and H. influenzae in vitro (MIC90s = <0.01-2 mg/L). Azithromycin increases survival in mouse models of intraperitoneal S. pyogenes, S. pneumoniae, E. faecalis, or H. influenzae infection (ED50s = 0.78, 8.7, 12.7, and 30.3 mg/kg, respectively). It inhibits replication of severe acute respiratory coronavirus 2 (SARS-CoV-2), but not Middle East respiratory syndrome CoV (MERS-CoV), when used at concentrations of 5 and 10 μM. Azithromycin also decreases plasma levels of IL-6, TNF-α, and IL-1β and increases survival in a mouse model of LPS-induced sepsis when administered at a dose of 100 mg/kg. Formulations containing azithromycin have been used in the treatment of a variety of bacterial infections. | [IC 50]
Macrolide | [References]
[1] M S KANATANI B J G. The new macrolides. Azithromycin and clarithromycin.[J]. The Western journal of medicine, 1994, 160 1: 31-37.
[2] D GIRARD. Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models.[J]. Journal of Antimicrobial Chemotherapy, 2005, 56 2: 365-371. DOI: 10.1093/jac/dki241
[3] AHMED MOSTAFA. FDA-Approved Drugs with Potent In Vitro Antiviral Activity against Severe Acute Respiratory Syndrome Coronavirus 2.[J]. ACS Applied Energy Materials, 2020. DOI: 10.3390/ph13120443
[4] ANASUYA PATEL. Azithromycin in Combination with Ceftriaxone Reduces Systemic Inflammation and Provides Survival Benefit in a Murine Model of Polymicrobial Sepsis.[J]. ACS Applied Energy Materials, 2018. DOI: 10.1128/aac.00752-18 |
|
| Company Name: |
Energy Chemical
|
| Tel: |
021-58432009 400-005-6266 |
| Website: |
http://www.energy-chemical.com |
|